<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04449588</url>
  </required_header>
  <id_info>
    <org_study_id>STS-BDB001-04</org_study_id>
    <nct_id>NCT04449588</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS</brief_title>
  <official_title>A Multi-center, Open-label, Randomized Parallel Controlled Evaluation on the Efficacy and Safety of BDB-001 Injection in the Treatment of Progressive Severe COVID-19 in Phase II/III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Staidson (Beijing) Biopharmaceuticals Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Defengrui Biotechnology Co. Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Staidson (Beijing) Biopharmaceuticals Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center, open, randomized study will evaluate the efficacy and safety of BDB-001&#xD;
      injection in severe COVID-19 with severe pneumonia, or acute lung injury/acute respiratory&#xD;
      distress syndrome. Patients will be randomized to two treatment arms (Arm A: Conventional&#xD;
      treatment + BDB-001; Arm B: Conventional treatment alone).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 23, 2020</start_date>
  <completion_date type="Anticipated">August 7, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to recovery of peripheral capillary oxygen saturation (SpO2) from baseline</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>28-day all-cause mortality rate</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who progress to critical severe</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving recovery in SpO2</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of PaO2/FiO2</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation time</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of oxygen therapy</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammation indicators (CRP or IL-6 etc.) from baseline</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in body temperature</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the clinical improvement based on ordinal scale recommended by the WHO R&amp;D Blueprint during treatment period</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement at D3, 7, 11 &amp; D14 based on ordinal scale recommended by the WHO R&amp;D Blueprint during treatment period</measure>
    <time_frame>Baseline，Day 3，Day 7，Day 11，Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to get categories 1 to 4 in the 8-points ordinal scale</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to attain an improvement of 1 point on the ordinal scale</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">368</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BDB-001 Injection</intervention_name>
    <description>BDB-001 Injection+Conventional treatment</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional treatment</intervention_name>
    <description>Conventional treatment only. Local guidelines should be integrated to choose the best supportive care.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years old ≤ age ≤ 80 years old, both men or women.&#xD;
&#xD;
          2. Confirmed SARS-CoV-2 infection, and meet at least one of the following criteria:&#xD;
&#xD;
             Confirmed severe COVID-19 in no more than 5 days who meets any of the following&#xD;
             criteria:&#xD;
&#xD;
               1. Respiratory distress, RR ≥ 30 times/min&#xD;
&#xD;
               2. Finger oxygen saturation (SpO2) ≤93% in resting state(room air)&#xD;
&#xD;
               3. Arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) ≤&#xD;
                  300 mmHg (1 mmHg = 0.133kpa) in supine position&#xD;
&#xD;
               4. Pulmonary imaging shows lesion progression &gt; 50% within 24-48 hours.&#xD;
&#xD;
             Symptoms,signs or chest imaging indicates ALI/ARDS;&#xD;
&#xD;
          3. Requiring a mask oxygen therapy,high-flow nasal cannula oxygen therapy(HFNC).&#xD;
&#xD;
          4. The informed consent form signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subject who meets any of the following criteria will be excluded from the trial:&#xD;
&#xD;
          1. Subjects already progressed into critically severe COVID-19 Critical severe standards&#xD;
             refer to FDA guidelines,as shown in Appendix 4 or sepsis and sepsis shock.&#xD;
&#xD;
          2. Concomitant with the following situation:severe lung disease such as chronic&#xD;
             obstructive pulmonary disease (moderate to severe type), lung cancers, active&#xD;
             tuberculosis; severe cardiovascular and cerebrovascular disease: unstable angina&#xD;
             pectoris, myocardial infarction, postcardiac surgery, cardiac function ≥ grade 3 (NYHA&#xD;
             Classification), or had undergone heart surgery within 6 months before randomization;&#xD;
             severe liver diseases (e.g. Child-Pugh score ≥ grade C); severe kidney diseases, such&#xD;
             as renal insufficiency (GFR ≤ 15 mL/min/1.73m^2); immune deficiencies or&#xD;
             immune-related diseases : including organ or bone marrow transplantation, some&#xD;
             autoimmune diseases, IgG4-related diseases, allergic alveolitis, vasculitis;&#xD;
             malignancies.&#xD;
&#xD;
          3. Subjects on current treatment with a complement inhibitor such as eculizumab within 1&#xD;
             month before randomization.&#xD;
&#xD;
          4. Subjects with hypersensitivity history to any ingredient contained in the drug.&#xD;
&#xD;
          5. A subject has used the following drugs within 2 weeks prior to screening procedures:&#xD;
&#xD;
               -  Calcineurin inhibitors (e.g., ciclosporin, tacrolimus, etc.)&#xD;
&#xD;
               -  Proliferation inhibitors (e.g., everolimus, sirolimus, etc.)&#xD;
&#xD;
               -  Anti-metabolic drugs (e.g., mycophenolate mofetil, mycophenolate, purine&#xD;
                  sulphate, etc.)&#xD;
&#xD;
               -  Recombinant human granulocyte macrophage colony stimulating factor&#xD;
                  (rhGM-CSF)/recombinant human granulocyte colony stimulating factor (rhG-CSF)&#xD;
&#xD;
          6. Pregnant or lactating woman.&#xD;
&#xD;
          7. Subjects who have participated in other interventional clinical trials in the last 3&#xD;
             months or during this trial.&#xD;
&#xD;
          8. Any other circumstances that the investigator considers inappropriate for the&#xD;
             participation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qing Mao, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southwest Hospital of Chongqing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Du Zhouqi</last_name>
    <phone>+86 17600505723</phone>
    <email>duzhouqi@staidson.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asgar Ali Hospital</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samira Ahmed</last_name>
      <phone>+880 17 3341 1279</phone>
      <email>samira@asgaralihospital.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bangladesh Specialized Hospital</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohiuddin Ahmed</last_name>
      <phone>+880 17 1404 6154</phone>
      <email>m77ahmed@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southwest Hospital Chongqing</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucan Jiang</last_name>
      <phone>+86 023 68754814</phone>
      <email>xnyyec@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Noble Hospital Pvt Ltd</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ameet Dravid</last_name>
      <phone>9975619766</phone>
      <email>ameet.dravid@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Government Medical College and Hospital</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atul Rajkondawar</last_name>
      <phone>9373215775</phone>
      <email>atul.rajkondawar@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>RSUD Cengkareng(Cengkareng General Hospital)</name>
      <address>
        <city>Jakarta</city>
        <state>Jakrata</state>
        <zip>11730</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Puji Astuti</last_name>
      <phone>0818731171</phone>
      <email>pujiastutidr@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>RSUD Pasar Minggu(Pasar Minggu General Hospital)</name>
      <address>
        <city>Jakarta</city>
        <zip>12550</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sri Dhuny Asri</last_name>
      <phone>0811181158</phone>
      <email>dhunyatasasri@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>RSUP Persahabatan(Persahabatan General Hospital)</name>
      <address>
        <city>Jakarta</city>
        <zip>13230</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erlina Burhan</last_name>
      <phone>08161628471</phone>
      <email>erlina_burhan@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 De Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Lalueza</last_name>
      <phone>647 746 471</phone>
      <email>lalueza@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicente Estrada Pérez</last_name>
      <phone>609292882</phone>
      <email>vicente.estrada@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio de los Santos Gil</last_name>
      <phone>915 202 222</phone>
      <email>isantosg@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Díaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Górgolas Hernández-Mora</last_name>
      <phone>629638289</phone>
      <email>MGORGOLAS@FJD.ES</email>
    </contact>
  </location>
  <location_countries>
    <country>Bangladesh</country>
    <country>China</country>
    <country>India</country>
    <country>Indonesia</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/15771587/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/30229880/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/26060601/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/25433014/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/23526211/</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol. 2005;23:821-52. doi: 10.1146/annurev.immunol.23.021704.115835.</citation>
    <PMID>15771587</PMID>
  </reference>
  <reference>
    <citation>Wood AJT, Vassallo A, Summers C, Chilvers ER, Conway-Morris A. C5a anaphylatoxin and its role in critical illness-induced organ dysfunction. Eur J Clin Invest. 2018 Dec;48(12):e13028. doi: 10.1111/eci.13028. Epub 2018 Oct 15.</citation>
    <PMID>30229880</PMID>
  </reference>
  <reference>
    <citation>Wang R, Xiao H, Guo R, Li Y, Shen B. The role of C5a in acute lung injury induced by highly pathogenic viral infections. Emerg Microbes Infect. 2015 May;4(5):e28. doi: 10.1038/emi.2015.28. Epub 2015 May 6.</citation>
    <PMID>26060601</PMID>
  </reference>
  <reference>
    <citation>Sun S, Zhao G, Liu C, Fan W, Zhou X, Zeng L, Guo Y, Kou Z, Yu H, Li J, Wang R, Li Y, Schneider C, Habel M, Riedemann NC, Du L, Jiang S, Guo R, Zhou Y. Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys. Clin Infect Dis. 2015 Feb 15;60(4):586-95. doi: 10.1093/cid/ciu887. Epub 2014 Nov 27.</citation>
    <PMID>25433014</PMID>
  </reference>
  <reference>
    <citation>Sun S, Zhao G, Liu C, Wu X, Guo Y, Yu H, Song H, Du L, Jiang S, Guo R, Tomlinson S, Zhou Y. Inhibition of complement activation alleviates acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection. Am J Respir Cell Mol Biol. 2013 Aug;49(2):221-30. doi: 10.1165/rcmb.2012-0428OC.</citation>
    <PMID>23526211</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 26, 2020</study_first_submitted>
  <study_first_submitted_qc>June 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2020</study_first_posted>
  <last_update_submitted>December 29, 2021</last_update_submitted>
  <last_update_submitted_qc>December 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Severe Pneumonia</keyword>
  <keyword>ALI/ARDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04449588
org study id: STS-BDB001-04
nct id: NCT04449588
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
This multi-center, open, randomized study will evaluate the efficacy and safety of BDB-001
      injection in severe COVID-19 with severe pneumonia, or acute lung injury/acute respiratory
      distress syndrome. Patients will be randomized to two treatment arms (Arm A: Conventional
      treatment + BDB-001; Arm B: Conventional treatment alone).
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Time to recovery of peripheral capillary oxygen saturation (SpO2) from baseline
time frame: Baseline to Day 28
measure: 28-day all-cause mortality rate
time frame: Baseline to Day 28
measure: Percentage of patients who progress to critical severe
time frame: Baseline to Day 28
measure: Percentage of subjects achieving recovery in SpO2
time frame: Baseline to Day 28
measure: Mean change of PaO2/FiO2
time frame: Baseline to Day 28
measure: Mechanical ventilation time
time frame: Baseline to Day 28
measure: Time of oxygen therapy
time frame: Baseline to Day 28
measure: Change in inflammation indicators (CRP or IL-6 etc.) from baseline
time frame: Baseline to Day 28
measure: Improvement in body temperature
time frame: Baseline to Day 28
measure: Mean change from baseline in the clinical improvement based on ordinal scale recommended by the WHO R&D Blueprint during treatment period
time frame: Baseline to Day 28
measure: Improvement at D3, 7, 11 & D14 based on ordinal scale recommended by the WHO R&D Blueprint during treatment period
time frame: Baseline，Day 3，Day 7，Day 11，Day 14
measure: Time to get categories 1 to 4 in the 8-points ordinal scale
time frame: Baseline to Day 28
measure: Time to attain an improvement of 1 point on the ordinal scale
time frame: Baseline to Day 28
arm group label: Treatment group
arm group type: Experimental
arm group label: Control group
arm group type: Experimental
intervention type: Drug
intervention name: BDB-001 Injection
description: BDB-001 Injection+Conventional treatment
arm group label: Treatment group
intervention type: Other
intervention name: Conventional treatment
description: Conventional treatment only. Local guidelines should be integrated to choose the best supportive care.
arm group label: Control group
criteria: 
gender: All
minimum age: 18 Years
maximum age: 80 Years
healthy volunteers: No
last name: Qing Mao, Ph.D
role: Principal Investigator
affiliation: Southwest Hospital of Chongqing
last name: Du Zhouqi
phone: +86 17600505723
email: duzhouqi@staidson.com
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
country: Bangladesh
country: China
country: India
country: Indonesia
country: Spain
url: https://pubmed.ncbi.nlm.nih.gov/15771587/
description: Related Info
url: https://pubmed.ncbi.nlm.nih.gov/30229880/
description: Related Info
url: https://pubmed.ncbi.nlm.nih.gov/26060601/
description: Related Info
url: https://pubmed.ncbi.nlm.nih.gov/25433014/
description: Related Info
url: https://pubmed.ncbi.nlm.nih.gov/23526211/
description: Related Info
citation: Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol. 2005;23:821-52. doi: 10.1146/annurev.immunol.23.021704.115835.
PMID: 15771587
citation: Wood AJT, Vassallo A, Summers C, Chilvers ER, Conway-Morris A. C5a anaphylatoxin and its role in critical illness-induced organ dysfunction. Eur J Clin Invest. 2018 Dec;48(12):e13028. doi: 10.1111/eci.13028. Epub 2018 Oct 15.
PMID: 30229880
citation: Wang R, Xiao H, Guo R, Li Y, Shen B. The role of C5a in acute lung injury induced by highly pathogenic viral infections. Emerg Microbes Infect. 2015 May;4(5):e28. doi: 10.1038/emi.2015.28. Epub 2015 May 6.
PMID: 26060601
citation: Sun S, Zhao G, Liu C, Fan W, Zhou X, Zeng L, Guo Y, Kou Z, Yu H, Li J, Wang R, Li Y, Schneider C, Habel M, Riedemann NC, Du L, Jiang S, Guo R, Zhou Y. Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys. Clin Infect Dis. 2015 Feb 15;60(4):586-95. doi: 10.1093/cid/ciu887. Epub 2014 Nov 27.
PMID: 25433014
citation: Sun S, Zhao G, Liu C, Wu X, Guo Y, Yu H, Song H, Du L, Jiang S, Guo R, Tomlinson S, Zhou Y. Inhibition of complement activation alleviates acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection. Am J Respir Cell Mol Biol. 2013 Aug;49(2):221-30. doi: 10.1165/rcmb.2012-0428OC.
PMID: 23526211
responsible party type: Sponsor
mesh term: COVID-19
mesh term: Pneumonia
sharing ipd: No